Updated Thoughts on Recro Pharma

November 3, 2020

When Recro Pharma announced weak first quarter results in May, I closed my recommendation and recommended selling at $5 or better.

Are you a member but not signed in? Click here to sign into your account.

Not a Member yet? Click here to learn about our service.

Our Members enjoy exclusive access to detailed analysis on under-the-radar spin-offs before they are profiled on Seeking Alpha, Value Investor Club, or SumZero.

Join Now